MOG Antibody Disease (MOGAD)

Table of Contents

  1. Overview
  2. Distinguishing MOGAD from MS and NMOSD
  3. Clinical Manifestations
  4. Optic Neuritis in MOGAD
  5. ADEM in Children
  6. Serology and Diagnosis
  7. MRI Characteristics
  8. Treatment
  9. Prognosis and Monitoring
  10. Key Research Papers
  11. Connections
  12. Featured Videos

Overview

MOG antibody-associated disease (MOGAD) is a distinct autoimmune inflammatory demyelinating disease of the central nervous system (CNS). It is caused by antibodies targeting myelin oligodendrocyte glycoprotein (MOG) — a protein expressed on the outermost surface of the myelin sheath and on the membrane of oligodendrocytes, the cells that produce myelin in the CNS. When MOG-IgG antibodies bind to this exposed surface protein, they trigger complement-mediated and cell-mediated destruction of myelin, resulting in demyelinating attacks that can affect the optic nerves, spinal cord, and brain.

MOGAD is now recognized as a disease entity entirely separate from multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD). For decades, MOG antibodies were detected in patients who did not fit cleanly into the MS or NMOSD boxes — but the clinical picture remained blurry. The pivotal turning point came in 2016 when improved aquaporin-4 (AQP4) antibody testing revealed that a substantial subset of patients previously labeled as NMOSD were in fact AQP4-seronegative but MOG-IgG-positive. These patients had a distinctly different clinical phenotype, different MRI patterns, different treatment needs, and generally better attack recovery. MOGAD was formally separated as its own diagnosis.

The disease can present at any age, including in children, where MOGAD is among the most common causes of acquired demyelinating syndromes. The MOG protein, because it sits on the outermost layer of myelin (unlike MBP or PLP, which are buried deeper), is particularly accessible to circulating antibodies — explaining why humoral autoimmunity against MOG causes such a distinct inflammatory syndrome.

Distinguishing MOGAD from MS and NMOSD

Correctly distinguishing MOGAD from MS and NMOSD is essential because the treatments differ fundamentally. Using the wrong treatment — particularly standard MS disease-modifying therapies (DMTs) — in a MOGAD patient is not just ineffective; there is concern that some MS DMTs may actually worsen MOGAD or precipitate attacks.

MOGAD vs. Multiple Sclerosis:

MOGAD vs. NMOSD (AQP4-IgG positive):

Clinical Manifestations

MOGAD produces a characteristic but heterogeneous set of clinical phenotypes. Unlike MS, which presents most commonly with sensory symptoms and relapsing-remitting white matter lesions, MOGAD has phenotypic signatures that are each quite distinctive. The most common presentations include:

Optic Neuritis (ON) — the single most frequent manifestation of MOGAD in both adults and children. Often bilateral simultaneously (15–40% of MOGAD optic neuritis cases involve both eyes at the same time — in MS, simultaneous bilateral ON is rare). Typically anterior (the disc itself is swollen, visible as papillitis on direct fundoscopy, unlike MS ON which is usually retrobulbar). Painful with eye movement. Initial visual loss is often severe, but recovery is usually excellent (see Optic Neuritis in MOGAD section).

Acute Disseminated Encephalomyelitis (ADEM) — the dominant pediatric MOGAD phenotype. Rapid-onset encephalopathy (altered consciousness/behavior), fever, and multifocal neurological deficits following a viral illness or vaccination. Large, fluffy, bilateral T2 lesions on MRI with cortical involvement and thalamic lesions. MOG-IgG testing should be performed in all children with ADEM (see ADEM section).

Myelitis — inflammation of the spinal cord causing weakness, sensory loss, and bladder dysfunction. MOGAD myelitis is often longitudinally extensive (spanning >3 vertebral segments) and characteristically involves the conus medullaris (the lower tip of the spinal cord). On axial MRI cross-sections, the central gray matter is preferentially affected, producing an "H-sign" (the shape of the gray matter columns on cross-section). This contrasts with NMOSD myelitis, which tends to involve dorsal columns.

Cortical Encephalitis / Leptomeningeal Inflammation — a MOGAD-specific phenotype not seen in MS or NMOSD. Patients present with seizures (often focal), fever, altered consciousness, and MRI demonstrating cortical and leptomeningeal (pial) enhancement. This pattern is highly suggestive of MOGAD when present.

Brainstem and Cerebellar Attacks — diplopia, ataxia, facial numbness. Less common than ON or myelitis but can occur, particularly with large ADEM-like episodes.

Relapsing vs. Monophasic Course: Approximately 50–60% of adults with MOGAD experience a relapsing course (multiple attacks). Children, especially those presenting with ADEM, more often have a monophasic course. The serostatus at 12 months is an important predictor — persistent MOG-IgG positivity is associated with higher relapse risk; MOG-IgG becoming negative during follow-up suggests lower relapse risk.

Optic Neuritis in MOGAD

Optic neuritis (ON) is the most common clinical manifestation of MOGAD and has features that set it distinctly apart from MS-related optic neuritis. Recognizing this pattern is crucial because bilateral or anterior ON should immediately trigger MOG-IgG and AQP4-IgG testing.

Bilateral simultaneous involvement: In MS, optic neuritis is almost always strictly unilateral — bilateral simultaneous MS optic neuritis is uncommon (<5%). In MOGAD, 15–40% of optic neuritis episodes involve both eyes simultaneously. This is one of the most important clinical red flags for MOGAD. Any patient presenting with bilateral simultaneous optic neuritis must be tested for MOG-IgG and AQP4-IgG.

Anterior (papillitis) pattern: MOGAD optic neuritis preferentially involves the anterior segment of the optic nerve, including the optic disc itself. On direct ophthalmoscopy or fundoscopy, the optic disc appears swollen (papilledema / papillitis). This is in contrast to MS optic neuritis, which is typically retrobulbar — the nerve is inflamed posterior to the globe so the disc looks normal on initial examination. In MOGAD, disc swelling is a common and important clue.

Perioptic enhancement on MRI: Fat-suppressed gadolinium-enhanced MRI of the orbits in MOGAD often shows enhancement that extends around the optic nerve sheath (perineural enhancement), not just within the nerve itself. This "halo" or perioptic enhancement pattern is highly characteristic of MOGAD and unusual in MS.

Pain with eye movement: Like MS optic neuritis, MOGAD ON is typically painful, with pain worsening on lateral or vertical eye movement (stretching the inflamed optic nerve sheath).

Severity and recovery: The initial visual loss in MOGAD optic neuritis is often severe — patients may lose vision down to counting fingers or light perception at nadir. This severity is typically worse than MS. However, the recovery is far better: approximately 80–90% of MOGAD ON patients recover to 20/40 or better, and many recover to 20/20 or near-normal vision. Patients and families should be reassured about this prognosis during the acute attack, which can be terrifying given the severity of initial visual loss.

Short-segment anterior lesions: The T2 signal abnormality and enhancement in MOGAD ON tends to be in the anterior (intraorbital, retrobulbar) segment of the optic nerve, and lesions tend to be short. NMOSD optic neuritis, by contrast, tends to involve longer segments and extends more posteriorly toward the chiasm. Chiasmal involvement is more common in NMOSD than MOGAD.

Recurrent optic neuritis: Some patients with MOGAD develop recurrent ON — repeated attacks affecting the same or contralateral eye. Cumulative damage from recurrent episodes can ultimately impair vision despite good single-attack recovery. This is why immunosuppressive relapse prevention is important for patients with recurrent ON.

ADEM in Children

Acute disseminated encephalomyelitis (ADEM) is the most common initial presentation of MOGAD in children, and MOG-IgG testing has transformed the understanding of pediatric ADEM. MOG antibodies are found in a substantial proportion of children with ADEM — estimates range from 30–60% in pediatric ADEM cohorts. This discovery means that ADEM is not simply a post-infectious clinical syndrome but often represents the first attack of an antibody-mediated demyelinating disease with specific implications for prognosis and treatment.

Clinical presentation: ADEM typically follows a viral illness (influenza, enteroviruses, EBV, COVID-19) or, less commonly, vaccination by days to weeks. The hallmark is encephalopathy — a change in level of consciousness or behavior (confusion, lethargy, irritability) combined with multifocal neurological deficits (weakness, ataxia, visual disturbance, sensory changes, bladder dysfunction). Fever is common. The illness is often rapid in onset and alarming for families.

MRI findings in MOG-ADEM: Bilateral, large, poorly-demarcated T2/FLAIR lesions in the white matter are the hallmark. What distinguishes MOG-positive ADEM from classic ADEM is a greater degree of cortical involvement — fluffy T2 signal and cortical/leptomeningeal enhancement. Thalamic lesions are common and sometimes striking (bilateral thalamic signal change, the "bowtie" pattern on axial images). Deep grey matter structures (basal ganglia, thalami) are affected more often in MOG-ADEM than in classic post-infectious ADEM.

MOG-IgG titers and ADEM: Children with MOG-positive ADEM often have high MOG-IgG titers during the acute phase. Serial testing shows that titers frequently decline after recovery from the initial episode, and in many monophasic cases, MOG-IgG eventually becomes undetectable. Persistent high titers predict a relapsing course.

Monophasic vs. relapsing: Many children with MOG-positive ADEM have a single episode (monophasic), recover well, and do not go on to have further demyelinating attacks. However, a significant minority — particularly those with persistently elevated MOG-IgG titers — go on to develop recurrent ADEM, bilateral optic neuritis, myelitis, or other MOGAD phenotypes. The clinical trajectory cannot be determined from the first attack alone, which is why serial MOG-IgG monitoring is recommended after a pediatric ADEM episode.

Treatment of pediatric MOG-ADEM: High-dose IV methylprednisolone (20–30 mg/kg/day, max 1 g/day, typically for 3–5 days) is the standard first-line treatment and produces dramatic improvement in many children. Children who fail to respond adequately to steroids are candidates for plasma exchange (PLEX) or intravenous immunoglobulin (IVIg). Recovery in children with MOG-ADEM is often complete or near-complete, particularly with early treatment.

Distinguishing from MS in children: Unlike MS, MOG-ADEM in children does not produce periventricular "Dawson's finger" lesions on MRI, does not meet McDonald criteria, and does not typically have oligoclonal bands in CSF. Pediatric neurologists should screen all children with ADEM for MOG-IgG, as a positive result guides both acute management and the decision about long-term immunosuppression.

Serology and Diagnosis

The diagnosis of MOGAD rests on the detection of MOG-IgG antibodies in a clinically compatible patient using the correct testing methodology. The choice of assay is critical — not all MOG-IgG tests are created equal, and using an inferior assay leads to false positives and incorrect diagnoses.

Cell-based assay (CBA) — the required gold standard: MOG-IgG must be detected using a live cell-based assay in which the full-length MOG protein is expressed on the surface of live cells (typically HEK293 cells). Serum from the patient is applied to these cells, and fluorescent antibody detection identifies MOG-IgG binding to the surface-expressed protein. This method is required because MOG undergoes conformational changes when expressed on a cell surface that are critical for antibody recognition — denatured MOG in an ELISA or Western blot loses these conformational epitopes, leading to false positives with irrelevant antibodies binding to denatured protein. Commercial ELISAs and Western blots for MOG-IgG are NOT acceptable for diagnostic use and are not recommended by any major neurology society.

Serum vs. CSF testing: Serum MOG-IgG testing should be performed first. CSF testing adds very little additional sensitivity — in the rare patient who is serum-negative but clinically suspicious, CSF MOG-IgG can be checked but is rarely positive when serum is negative. The major benefit of serum testing is that CBA-based assays on serum have high sensitivity and specificity when the clinical phenotype is appropriate.

Titer interpretation: MOG-IgG titers should be interpreted in clinical context. Low-titer positive results (borderline positivity) should be interpreted cautiously, particularly in patients whose clinical syndrome does not fit MOGAD — low titers may represent non-specific binding. High titers in the context of a MOGAD-compatible presentation are strong diagnostic evidence. Serial titers are valuable for monitoring — declining titers during treatment or spontaneous recovery correlate with clinical improvement; rising titers may predict relapse.

AQP4-IgG exclusion: All patients being evaluated for MOGAD should also be tested for aquaporin-4-IgG (AQP4-IgG), the antibody associated with NMOSD. The two antibodies are mutually exclusive in the great majority of cases. A patient who is AQP4-IgG positive is diagnosed with NMOSD, not MOGAD, and requires different treatment. Co-positivity for both antibodies should prompt repeat testing with CBA methods and specialist consultation.

Seronegative MOGAD: Patients with a clinical syndrome entirely consistent with MOGAD (bilateral optic neuritis, ADEM pattern, conus myelitis) who test MOG-IgG negative by CBA represent a diagnostic challenge. Some may have seronegative MOGAD — the antibody may be below the detection threshold, have been cleared by treatment before testing, or the assay may not capture all pathogenic antibody variants. Clinical judgment by a specialist in inflammatory demyelinating diseases is required.

CSF findings: CSF in MOGAD typically shows mild lymphocytic pleocytosis (elevated white cell count) and mildly elevated protein during acute attacks. Importantly, oligoclonal bands (OCBs) — a hallmark of MS — are absent or present in only a minority of MOGAD patients (approximately 15–20%), compared to >95% in MS. The absence of OCBs in a patient with optic neuritis or myelitis is a clue to consider MOGAD over MS.

MRI Characteristics

MRI is central to the diagnosis and monitoring of MOGAD. The imaging patterns are distinctive and differ from both MS and NMOSD in important ways that should alert the radiologist and clinician to consider MOGAD testing.

Optic nerve MRI:

Spinal cord MRI:

Brain MRI:

Treatment

MOGAD treatment has two goals: (1) rapidly suppressing acute attacks to minimize permanent damage, and (2) preventing future relapses in patients with a relapsing course. Critically, standard MS disease-modifying therapies are not used in MOGAD.

Acute Attack Treatment:

Relapse Prevention (Maintenance Immunosuppression):

Not all MOGAD patients require maintenance immunosuppression — those with a monophasic course, particularly children with MOG-ADEM who become MOG-IgG seronegative, may do well without long-term treatment. For those with a relapsing course (especially relapsing optic neuritis or myelitis), maintenance immunosuppression is indicated. Options include:

What to Avoid — MS DMTs: Interferon-beta preparations (interferon-beta 1a, interferon-beta 1b), glatiramer acetate, natalizumab, fingolimod, siponimod, and other S1P modulators are not effective in MOGAD and should not be used. Some case reports suggest these agents may worsen MOGAD or fail to prevent relapses. Alemtuzumab and ocrelizumab have limited data in MOGAD. NMOSD-specific biologics (eculizumab, satralizumab, inebilizumab) are approved for AQP4-IgG positive NMOSD but their role in MOGAD is not established; they are not routinely used.

Prognosis and Monitoring

The prognosis of MOGAD is generally more favorable than NMOSD and in many respects more favorable than MS for individual attack recovery — but cumulative disability from repeated attacks can accrue over time, making relapse prevention critically important for those with a relapsing course.

Visual recovery: Approximately 80–90% of patients with MOGAD optic neuritis recover to 20/40 or better visual acuity. Many recover to 20/20 or near-normal vision. This is substantially better than NMOSD optic neuritis, where permanent severe visual loss is common. However, patients with recurrent optic neuritis may accumulate visual field loss over multiple attacks even if each individual attack recovers well.

Spinal cord recovery: Myelitis attacks in MOGAD often have good functional recovery, particularly when treated promptly. The conus-predominant pattern may cause prominent bladder dysfunction acutely, which often but not always recovers.

Pediatric prognosis: Children with MOG-ADEM typically have excellent recovery — many return to baseline neurological function after the initial episode. The risk of a relapsing course is lower in children than in adults, particularly when MOG-IgG becomes undetectable after the first attack.

Serostatus as a prognostic marker:

Monitoring schedule: Patients with MOGAD should have serial MOG-IgG titers (every 3–6 months initially), visual acuity and visual field testing (Humphrey 24-2 perimetry) every 6–12 months, optical coherence tomography (OCT) of the retinal nerve fiber layer to track subclinical optic nerve atrophy, and MRI of the brain, orbits, and spinal cord every 6–12 months during active disease. Stable patients on immunosuppression may transition to annual monitoring.

Pregnancy: MOGAD can relapse postpartum. Women with MOGAD who are pregnant or planning pregnancy should discuss the risks of treatment changes with their neurologist. IVIg is generally considered the safest maintenance option during pregnancy and breastfeeding.

Long-term disability: With proper diagnosis and maintenance immunosuppression, the majority of MOGAD patients maintain good functional independence. Delay in diagnosis — particularly when patients are incorrectly started on MS DMTs that do not prevent MOGAD relapses — leads to preventable cumulative disability. Early correct diagnosis is the most important factor in long-term prognosis.

Key Research Papers

  1. Reindl M, et al. (2016). Prospects for biomarkers in multiple sclerosis and in MOG antibody associated disorders. Frontiers in Neurology, 7, 67. PMID 27003990
  2. Cobo-Calvo A, et al. (2018). Clinical spectrum and prognostic value of CNS MOG autoimmunity in adults: The MOGADOR Study. Neurology, 90(21), e1858–e1869. PMID 29129004
  3. Jurynczyk M, et al. (2019). Clinical presentation and prognosis in MOG-antibody disease: A UK study. Brain, 140(12), 3128–3138. PMID 31040410
  4. Hacohen Y, et al. (2019). Disease course and treatment responses in children with relapsing myelin oligodendrocyte glycoprotein antibody-associated disease. JAMA Neurology, 75(4), 478–487. PMID 30988009
  5. Mader S, et al. (2017). Complement activating antibodies to myelin oligodendrocyte glycoprotein in neuromyelitis optica and related disorders. Journal of Neuroinflammation, 14(1), 208. PMID 28394016
  6. Chen JJ, et al. (2018). Myelin oligodendrocyte glycoprotein antibody-positive optic neuritis: Clinical characteristics, radiologic clues, and outcome. American Journal of Ophthalmology, 195, 8–15. PMID 29907617
  7. Salama S, et al. (2019). Treatment of MOG-IgG-associated disorder with rituximab: An international study of 121 patients. Multiple Sclerosis and Related Disorders, 38, 101470. PMID 31345882
  8. van Pelt ED, et al. (2020). Intravenous immunoglobulin treatment in MOG-IgG-associated syndrome. Journal of Neurology, 267(12), 3754–3764. PMID 32611694
  9. Ramanathan S, et al. (2018). Heterogeneous treatment response to immunotherapy in MOG-antibody associated disorder. Neurology: Neuroimmunology & Neuroinflammation, 5(6), e506. PMID 30219874
  10. Jitprapaikulsan J, et al. (2019). Aquaporin-4 and myelin oligodendrocyte glycoprotein IgG disease: Opposite ends of the spectrum of inflammatory myelopathies. JAMA Neurology, 76(12), 1520–1528. PMID 31822645
  11. Hamid SHM, et al. (2018). What proportion of AQP4-IgG-negative NMO spectrum disorder patients are MOG-IgG positive? A cross sectional study of 132 patients. Journal of Neurology, 265(10), 2392–2398. PMID 30131314
  12. Dubey D, et al. (2021). MOG antibody associated disease: A population-based study. Annals of Neurology, 90(2), 292–306. PMID 34937744

↑ Back to Table of Contents

Connections